Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medrad has received FDA 510(k) clearance for a new fluorodeoxyglucose infusion system for positron emission tomography/computed tomography imaging procedures.
Subscribe to our email newsletter
The new Intego positron emission tomography infusion system is claimed to be the first infusion system available in the US to automate the fluorodeoxyglucose (FDG) delivery process.
According to the company, the new Intego system enables healthcare providers to easily administer FDG at any time throughout the day and enhances the clinician’s ability to deliver FDG with precision, flexibility and safety.
Cliff Kress, senior vice president of the CT business unit at Medrad, said: “Medrad has a strong heritage of developing innovative products to improve fluid delivery for cardiovascular, magnetic resonance and computed tomography imaging procedures. With our new Intego system that fully automates FDG delivery, we can once again improve how molecular imaging is done.”